Werkgroep Cardiologische centra Nederland

SURPASS–CVOT (Follow-up)

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes
Medicine
Tirzepatide
Population
Diabetes mellitus
Phase
III
Starting year
2019
More information
Clinicaltrials.gov

Director of Study

dr. F.J.F. Broeyer (Cardioloog)
Amstelveen, Ziekenhuis Amstelland